{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["49"],"submitter":["Penault-Llorca F"],"pubmed_abstract":["<h4>Purpose</h4>Genomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy. Such tests seem especially interesting in \"intermediate\" clinico-pathological risk categories. The psychological impact of the decision uncertainty in these women remains largely unexplored. We assessed the clinical and psychological impact of EndoPredict® (EpClin), a clinico-genomic test, in these patients.<h4>Methods</h4>This multicenter, single arm prospective study (NCT02773004) enrolled patients for which adjuvant chemotherapy was uncertain, based on predefined criteria. The primary endpoint was the proportion of change between initial adjuvant decision and final administration of chemotherapy. Secondary endpoints included post-test (Day"],"journal":["Breast (Edinburgh, Scotland)"],"pagination":["132-140"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7375561"],"repository":["biostudies-literature"],"pubmed_title":["Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14)."],"pmcid":["PMC7375561"],"pubmed_authors":["Arnaud A","Valent A","Derbel O","Boinon D","Guiu S","Levy C","Le Rol A","Lortholary A","Jacquin JP","Penault-Llorca F","Uwer L","Quenel-Tueux N","Foa C","Catala S","Kwiatkowski F","Guardiola E","Girre V","Leheurteur M","Lemonnier J","Jouannaud C","Delaloge S"],"additional_accession":[]},"is_claimable":false,"name":"Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).","description":"<h4>Purpose</h4>Genomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy. Such tests seem especially interesting in \"intermediate\" clinico-pathological risk categories. The psychological impact of the decision uncertainty in these women remains largely unexplored. We assessed the clinical and psychological impact of EndoPredict® (EpClin), a clinico-genomic test, in these patients.<h4>Methods</h4>This multicenter, single arm prospective study (NCT02773004) enrolled patients for which adjuvant chemotherapy was uncertain, based on predefined criteria. The primary endpoint was the proportion of change between initial adjuvant decision and final administration of chemotherapy. Secondary endpoints included post-test (Day","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Feb","modification":"2026-04-07T22:31:56.978Z","creation":"2020-11-19T13:30:44Z"},"accession":"S-EPMC7375561","cross_references":{"pubmed":["31790959"],"doi":["10.1016/j.breast.2019.10.013"]}}